Clinical trials
Pharming announces positive data from paediatric clinical trial with RUCONEST®
Pharming Group N.V. today announced positive data from a clinical trial with the use of RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for the treatment of hereditary angioedema (HAE) attacks in children.
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema.
“The results of this study provide important safety and efficacy data on the use of RUCONEST® in children and show good clinical concordance with results from adolescents and adults with HAE.”
- Bruno Giannetti - COO